statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline...

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc purchased 8,374 shares of the business's stock in a transaction dated Monday, April 1st. The stock...

Perceptive Advisors Llc Acquires 8,374 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc purchased 309,847 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The...

Perceptive Advisors Llc Purchases 309,847 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report)s stock had its "buy" rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday...

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Reaffirmed by HC Wainwright

Investors considering a purchase of Aldeyra Therapeutics Inc (ALDX) stock, but cautious about paying the going market price of 3.42/share, might benefit from considering selling puts among the...

Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 25.2% Annualized Using Options

This is a Bullish indicator signaling ALDX's price could rise from here. Traders may explore going long the stock or buying call options...

Aldeyra Therapeutics (ALDX, $3.27) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

This is a signal that ALDX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Aldeyra Therapeutics (ALDX, $3.27) Stochastic Oscillator left the overbought zone on March 28, 2024

This price move could be a signal that ALDX may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Aldeyra Therapeutics (ALDX, $3.27) price may drop as it broke higher Bollinger Band on Mar 28, 2024

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Volume	182,527.00
52-Wk High	$11.97
52-Wk Low	$1.42

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.11	--	--	N/A
Q4'23	-$0.10	--	--	N/A
Q3'23	-$0.20	--	--	N/A
Q2'23	-$0.17	--	--	N/A
Q1'23	-$0.29	-$0.27	6.98%	BEAT

ALDX Aldeyra Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals